Hikma launches authorized generic of Xyrem (sodium oxybate) in the US

LONDON: Hikma Pharmaceuticals has launched an authorized generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution CIII. Hikma will have 180 days of marketing exclusivity for its authorized generic product in the US.

Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat the following symptoms in people 7 years of age or older with narcolepsy:

·      sudden onset of weak or paralyzed muscles (cataplexy)

·      excessive daytime sleepiness (EDS)

Jazz Pharmaceuticals reported net sales for Xyrem® of $1.3 billion in 2021.

Brian Hoffmann, President of Generics said, “We are pleased to be able to provide the first authorized generic version of Xyrem® to patients and health care providers in the US. This launch further expands our diversified portfolio of generic products, and underscores our ability to put Better Health, Within Reach, Every Day®2 for the millions of people who rely on our medicines.”

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *